ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.32
(4.77%)
SEK 19.32
(4.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 109.36 Million SEK | -14.3% |
| 2022 | 127.61 Million SEK | 140.25% |
| 2021 | 53.11 Million SEK | 75.0% |
| 2020 | 30.35 Million SEK | 13.58% |
| 2019 | 26.72 Million SEK | 15.97% |
| 2018 | 23.04 Million SEK | 24.37% |
| 2017 | 18.52 Million SEK | 48.71% |
| 2016 | 12.45 Million SEK | 98.13% |
| 2015 | 6.28 Million SEK | 0.17% |
| 2014 | 6.27 Million SEK | 5.29% |
| 2013 | 5.96 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.07 Million SEK | -33.53% |
| 2024 Q2 | 9.71 Million SEK | -31.0% |
| 2023 Q2 | 34.17 Million SEK | 9.55% |
| 2023 Q4 | 21.17 Million SEK | -7.22% |
| 2023 FY | 109.36 Million SEK | -14.3% |
| 2023 Q3 | 22.82 Million SEK | -33.21% |
| 2023 Q1 | 31.19 Million SEK | -40.84% |
| 2022 Q3 | 31.84 Million SEK | 16.62% |
| 2022 FY | 127.61 Million SEK | 140.25% |
| 2022 Q4 | 52.72 Million SEK | 65.55% |
| 2022 Q2 | 27.31 Million SEK | 73.63% |
| 2022 Q1 | 15.72 Million SEK | -14.58% |
| 2021 Q3 | 12.33 Million SEK | 6.03% |
| 2021 Q1 | 11.01 Million SEK | 1.6% |
| 2021 Q2 | 11.63 Million SEK | 5.61% |
| 2021 FY | 53.11 Million SEK | 75.0% |
| 2021 Q4 | 18.41 Million SEK | 49.26% |
| 2020 Q2 | 6.54 Million SEK | -6.39% |
| 2020 Q1 | 6.99 Million SEK | -18.76% |
| 2020 Q3 | 5.96 Million SEK | -8.83% |
| 2020 FY | 30.35 Million SEK | 13.58% |
| 2020 Q4 | 10.84 Million SEK | 81.66% |
| 2019 Q4 | 8.6 Million SEK | 55.99% |
| 2019 Q1 | 6.07 Million SEK | -8.81% |
| 2019 FY | 26.72 Million SEK | 15.97% |
| 2019 Q3 | 5.51 Million SEK | -15.37% |
| 2019 Q2 | 6.52 Million SEK | 7.29% |
| 2018 Q1 | 5.08 Million SEK | 2.56% |
| 2018 FY | 23.04 Million SEK | 24.37% |
| 2018 Q3 | 5.13 Million SEK | -16.7% |
| 2018 Q2 | 6.16 Million SEK | 21.14% |
| 2018 Q4 | 6.66 Million SEK | 29.87% |
| 2017 Q1 | 4.16 Million SEK | -33.16% |
| 2017 Q3 | 4.69 Million SEK | -0.34% |
| 2017 Q4 | 4.95 Million SEK | 5.62% |
| 2017 FY | 18.52 Million SEK | 48.71% |
| 2017 Q2 | 4.71 Million SEK | 13.16% |
| 2016 Q4 | 6.22 Million SEK | 67.55% |
| 2016 Q2 | 2.36 Million SEK | -81.0% |
| 2016 FY | 12.45 Million SEK | 98.13% |
| 2016 Q1 | 12.45 Million SEK | 0.0% |
| 2016 Q3 | 3.71 Million SEK | 57.03% |
| 2015 FY | 6.28 Million SEK | 0.17% |
| 2014 FY | 6.27 Million SEK | 5.29% |
| 2013 FY | 5.96 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | -144.076% |
| Amniotics AB (publ) | 29.07 Million SEK | -276.197% |
| BioArctic AB (publ) | 89.62 Million SEK | -22.026% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 92.777% |
| Camurus AB (publ) | 1.05 Billion SEK | 89.679% |
| Cantargia AB (publ) | 290.01 Million SEK | 62.289% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -399.511% |
| CombiGene AB (publ) | 44.14 Million SEK | -147.752% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 23.512% |
| Genovis AB (publ.) | 88.19 Million SEK | -24.004% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 4.958% |
| Mendus AB (publ) | 129.13 Million SEK | 15.309% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1404.788% |
| Intervacc AB (publ) | 79.78 Million SEK | -37.078% |
| Kancera AB (publ) | 63.07 Million SEK | -73.388% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1881.663% |
| LIDDS AB (publ) | 27.75 Million SEK | -294.091% |
| Lipum AB (publ) | 37.3 Million SEK | -193.157% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1407.692% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 19.53% |
| NextCell Pharma AB | -576.01 Thousand SEK | 19086.874% |
| OncoZenge AB (publ) | 15.9 Million SEK | -587.633% |
| Saniona AB (publ) | 1.07 Million SEK | -10054.875% |
| Simris Alg AB (publ) | 38.64 Million SEK | -183.029% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 65.983% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 69.418% |
| Xintela AB (publ) | 57.31 Million SEK | -90.816% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 39.82% |
| Ziccum AB (publ) | 27.87 Million SEK | -292.309% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -646.386% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -286.1% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -566.837% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 64.386% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -156.54% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -518.492% |
| Corline Biomedical AB | 30.16 Million SEK | -262.53% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -88.465% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -31.501% |
| Aptahem AB (publ) | 10.01 Million SEK | -992.266% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 18.803% |
| Fluicell AB (publ) | 28.61 Million SEK | -282.178% |
| Biovica International AB (publ) | 133.72 Million SEK | 18.212% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -452.643% |
| AcouSort AB (publ) | 25.87 Million SEK | -322.662% |
| Abliva AB (publ) | 27.86 Million SEK | -292.478% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 43.479% |
| 2cureX AB (publ) | 36.51 Million SEK | -199.491% |
| I-Tech AB | 40.14 Million SEK | -172.412% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 87.275% |
| Cyxone AB (publ) | 28.21 Million SEK | -287.637% |
| Biosergen AB | 26.8 Million SEK | -307.953% |
| Nanologica AB (publ) | 69.88 Million SEK | -56.493% |
| SynAct Pharma AB | 224.49 Million SEK | 51.283% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -147.573% |
| BioInvent International AB (publ) | 441.4 Million SEK | 75.223% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -356.57% |
| Alzinova AB (publ) | 36.39 Million SEK | -200.495% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 62.254% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1292.111% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 1.394% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -644.0% |